Inhibiting DYRK1A may reduce the risk of developing neurological dysfunction and neurodegeneration in Trisomy 21/Down's syndrome individuals with elevated DYRK1A levels. However, tissue‐specific and isoform‐selective DYRK1A inhibitors [318, 319] may be required, as DYRK family members have other key functions. The gene discussed is DYRK1A; the disease is Down syndrome.